Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast
The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Clovis Oncology). In November 2022, Elahere (ImmunoGen) entered the U.S. market as the first antibody-drug conjugate for patients with folate receptor alpha (FRα)-positive tumors. The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with a variety of mechanisms of action are set to launch for ovarian cancer and further diversify treatment options.
Questions answered
- What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?
- What is the current treatment landscape for ovarian cancer? What are interviewed experts’ insights on current therapies?
- What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?
- What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- August 2023
- May 2023
- April 2023
- Q4 2022
- December 2022
- November 2022
- Market Outlook
- Key findings
- Market share of drug classes for ovarian cancer: 2022
- Market share of drug classes for ovarian cancer: 2032
- Drug-treatable population share and major-market sales share in ovarian cancer: 2022
- Drug-treatable population share and major-market sales share in ovarian cancer: 2032
- Population positioning of therapies in ovarian cancer: United States
- Population positioning of therapies in ovarian cancer: Europe
- Population positioning of therapies in ovarian cancer: Japan
- Ovarian cancer SWOT analysis
- Market drivers and constraints
- What factors are driving the market for ovarian cancer?
- What factors are constraining the market for ovarian cancer?
- Major-market sales for ovarian cancer by region: 2022-2032
- Major-market sales for ovarian cancer by drug class: 2022-2032
- Major-market sales of targeted therapies in the ovarian cancer market: 2022-2032
- Major-market sales of PARP inhibitors by patient population: 2022-2032
- Segment-specific trends
- Patient-share dynamics of key therapies (excluding maintenance) in first-line advanced-stage ovarian cancer in the United States: 2022-2032
- Patient-share dynamics of maintenance therapies in first-line advanced-stage ovarian cancer in the United States: 2022-2032
- Patient-share dynamics of key therapies excluding maintenance treatments in the second-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
- Patient-share dynamics of maintenance therapies in the second-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
- Patient-share dynamics of key therapies excluding maintenance treatments in the third-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
- Patient-share dynamics of maintenance therapies in the third-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
- Patient-share dynamics of second-line platinum-resistant and platinum-refractory ovarian cancer in the United States: 2022-2032
- Patient-share dynamics of third-line platinum-resistant and platinum-refractory ovarian cancer in the United States: 2022-2032
- Patient-share dynamics of key therapies in the fourth- and subsequent-line ovarian cancer setting in the United States: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Disease pathophysiology
- Disease pathogenesis
- Disease classification
- Ovarian cancer histologies
- Molecular subtypes and key pathways
- Screening tests: CA-125
- Staging and classification
- Staging and grading
- International Federation of Gynecology and Obstetrics staging system for cancer of the ovary, fallopian tube, and peritoneum
- Stage I-II
- Stage III-IV
- Key pathways and drug targets
- Key pathways and drug targets in ovarian cancer
- Key signaling pathways in epithelial cells
- PARP inhibition: mechanism of action
- Folate receptor pathway
- Immune checkpoint inhibitors and modulators
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancers: 2022-2032
- Disease definition, methods, and sources used
- Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer by stage: 2022-2032
- Disease definition, methods, and sources used
- Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer by BRCA mutation: 2022-2032
- Disease definition, methods, and sources used
- Recurrent incident cases of epithelial ovarian and fallopian tube cancer: 2022-2032
- Ovarian cancer patient flow
- Drug-treatable cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer: 2022-2032
- Drug-treated cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for ovarian cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for ovarian cancer
- Current treatments used for ovarian cancer
- Market events impacting the use of key current therapies in ovarian cancer
- Key results from select clinical trials investigating bevacizumab for the treatment of ovarian cancer
- Ongoing clinical development of bevacizumab
- Expert insight: bevacizumab
- Key results from select clinical trials investigating Lynparza for the treatment of ovarian cancer
- Ongoing clinical development of Lynparza
- Key ongoing clinical trials of Lynparza in the treatment of ovarian cancer
- Expert insight: Lynparza
- Key results from select clinical trials investigating Rubraca for the treatment of ovarian cancer
- Ongoing clinical development of Rubraca
- Key ongoing clinical trials investigating Rubraca in the treatment of ovarian cancer
- Expert insight: Rubraca
- Key results from select clinical trials investigating Zejula for the treatment of ovarian cancer
- Ongoing clinical development of Zejula
- Key ongoing clinical trials investigating Zejula in the treatment of ovarian cancer
- Expert insight: Zejula
- Key results of select clinical trials investigating Elahere for the treatment of ovarian cancer
- Ongoing clinical development of Elahere
- Key ongoing clinical trials of Elahere in the treatment of ovarian cancer
- Expert insight: Elahere
- Key results from select clinical trials investigating Yondelis for the treatment of ovarian cancer
- Ongoing clinical development of Yondelis
- Key results of select clinical trials investigating Mekinist for the treatment of ovarian cancer
- Ongoing clinical development of Mekinist
- Expert insight: Mekinist
- Medical practice
- Early-stage first-line ovarian cancer
- Advanced-stage first-line ovarian cancer
- Second- and third-line platinum-sensitive ovarian cancer
- Second- and third-line platinum-resistant and -refractory ovarian cancer
- Fourth- and subsequent-line ovarian cancer
- Country-specific ovarian cancer treatment guidelines
- Patient characteristics influencing drug selection in ovarian cancer
- Treatment decision tree for early- and advanced-stage ovarian cancer: United States
- Treatment decision tree for early- and advanced-stage ovarian cancer: Europe
- Treatment decision tree for early- and advanced-stage ovarian cancer: Japan
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in ovarian cancer
- Top unmet needs in ovarian cancer: current and future attainment
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for ovarian cancer
- Estimated market authorization dates of key emerging therapies for the treatment of ovarian cancer
- Key results of select clinical trials investigating Tecentriq for the treatment of ovarian cancer
- Key ongoing clinical trials of Tecentriq in the treatment of ovarian cancer
- Analysis of the clinical development program for Tecentriq
- Expert insight: Tecentriq
- Expectations for market authorization and sales opportunity of Tecentriq in ovarian cancer
- Key results of select clinical trials investigating Keytruda for the treatment of ovarian cancer
- Key ongoing clinical trials of Keytruda in the treatment of ovarian cancer
- Analysis of the clinical development program for Keytruda
- Expert insight: Keytruda
- Expectations for market authorization and sales opportunity of Keytruda in ovarian cancer
- Key results of select clinical trials investigating Opdivo for the treatment of ovarian cancer
- Key ongoing clinical trials of Opdivo in the treatment of ovarian cancer
- Analysis of the clinical development program for Opdivo
- Expert insight: Opdivo
- Expectations for market authorization and sales opportunity of Opdivo in ovarian cancer
- Key results of select clinical trials investigating Imfinzi for the treatment of ovarian cancer
- Analysis of the clinical development program for Imfinzi
- Expert insight: Imfinzi
- Expectations for market authorization and sales opportunity of Imfinzi in ovarian cancer
- Key results of select clinical trials investigating Jemperli for the treatment of ovarian cancer
- Key ongoing clinical trials of Jemperli in the treatment of ovarian cancer
- Analysis of the clinical development program for Jemperli
- Expert insight: Jemperli
- Expectations for market authorization and sales opportunity of Jemperli in ovarian cancer
- Key results of select clinical trials investigating olvimulogene nanivacirepvec for the treatment of ovarian cancer
- Key ongoing clinical trials of olvimulogene nanivacirepvec in the treatment of ovarian cancer
- Analysis of the clinical development program for olvimulogene nanivacirepvec
- Expectations for market authorization and sales opportunity of olvimulogene nanivacirepvec in ovarian cancer
- Key results of select clinical trials investigating relacorilant for the treatment of ovarian cancer
- Key ongoing clinical trials of relacorilant in the treatment of ovarian cancer
- Analysis of the clinical development program for relacorilant
- Expert insight: relacorilant
- Expectations for market authorization and sales opportunity of relacorilant in ovarian cancer
- Key results of select clinical trials investigating oregovomab for the treatment of ovarian cancer
- Key ongoing clinical trials of oregovomab in the treatment of ovarian cancer
- Analysis of the clinical development program for oregovomab
- Expert insight: oregovomab
- Expectations for market authorization and sales opportunity of oregovomab in ovarian cancer
- Key results of select clinical trials investigating Piqray for the treatment of ovarian cancer
- Key ongoing clinical trials of Piqray in the treatment of ovarian cancer
- Analysis of the clinical development program for Piqray
- Expert insight: Piqray
- Expectations for market authorization and sales opportunity of Piqray in ovarian cancer
- Key results of select clinical trials investigating batiraxcept for the treatment of ovarian cancer
- Analysis of the clinical development program for batiraxcept
- Expert insight: batiraxcept
- Expectations for market authorization and sales opportunity of batiraxcept in ovarian cancer
- Key ongoing clinical trials of nemvaleukin alfa in the treatment of ovarian cancer
- Analysis of the clinical development program for nemvaleukin alfa
- Expert insight: nemvaleukin alfa
- Expectations for market authorization and sales opportunity of nemvaleukin alfa in ovarian cancer
- Key results of select clinical trials investigating upifitamab rilsodotin for the treatment of ovarian cancer
- Key ongoing clinical trials of upifitamab rilsodotin in the treatment of ovarian cancer
- Analysis of the clinical development program for upifitamab rilsodotin
- Expert insight: upifitamab rilsodotin
- Expectations for market authorization and sales opportunity of upifitamab rilsodotin in ovarian cancer
- Key results of select clinical trials investigating navicixizumab for the treatment of ovarian cancer
- Key ongoing clinical trials of navicixizumab in the treatment of ovarian cancer
- Analysis of the clinical development program for navicixizumab
- Expert insight: navicixizumab
- Expectations for market authorization and sales opportunity of navicixizumab in ovarian cancer
- Early-phase pipeline analysis
- Select compounds in Phase 1/2 development for ovarian cancer
- Key findings
- Access and Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in ovarian cancer: United States
- General reimbursement environment: United States
- Key market access considerations in ovarian cancer: EU5
- General reimbursement environment: EU5
- Key market access considerations in ovarian cancer: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Ovarian cancer bibliography
- Key Findings
Marcos Fernández Alfara, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Fernández has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.